Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), and connected persons, specifically regarding increases in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On January 13, 2014, several directors and PDMRs increased their holdings in GlaxoSmithKline plc ordinary shares. These transactions were executed at a price of 1,597.03 pence per share and resulted from the re-investment of dividends paid to shareholders on January 9, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of insider share purchases compliant with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: January 13, 2014.
- Share Price: 1,597.03 pence per share.
- Transaction Type: Dividend re-investment leading to increased share ownership.
- Key Participants: Includes Dr. M M Slaoui (251,218 shares), Mr. S A Hussain (1,192,946 shares), and Dr. P J T Vallance (367,542 shares), among others.
- Notification Date: The company was advised of these transactions on January 16, 2014.